Pasireotide (SIGNIFOR) in acromegaly. After treatment failure: better than pegvisomant.
In a trial including 198 patients in whom several lines of treatments had failed, pasireotide normalised IGF-1 and GH levels and sometimes reduced the size of the pituitary adenoma, but often at a cost of developing diabetes.